Your browser doesn't support javascript.
loading
Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression.
Cohen-Dvashi, Hadas; Ben-Chetrit, Nir; Russell, Roslin; Carvalho, Silvia; Lauriola, Mattia; Nisani, Sophia; Mancini, Maicol; Nataraj, Nishanth; Kedmi, Merav; Roth, Lee; Köstler, Wolfgang; Zeisel, Amit; Yitzhaky, Assif; Zylberg, Jacques; Tarcic, Gabi; Eilam, Raya; Wigelman, Yoav; Will, Rainer; Lavi, Sara; Porat, Ziv; Wiemann, Stefan; Ricardo, Sara; Schmitt, Fernando; Caldas, Carlos; Yarden, Yosef.
Afiliação
  • Cohen-Dvashi H; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Ben-Chetrit N; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Russell R; Cancer Research UK Cambridge Research Institute Li Ka Shing Centre, Cambridge, UK.
  • Carvalho S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Lauriola M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Nisani S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Mancini M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Nataraj N; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Kedmi M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Roth L; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Köstler W; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Zeisel A; Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
  • Yitzhaky A; Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
  • Zylberg J; Chemical Physics, Weizmann Institute of Science, Rehovot, Israel.
  • Tarcic G; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Eilam R; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Wigelman Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Will R; Division of Molecular Genome Analysis, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Lavi S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Porat Z; Biological Services, Weizmann Institute of Science, Rehovot, Israel.
  • Wiemann S; Division of Molecular Genome Analysis, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Ricardo S; IPATIMUP - Institute of Molecular Pathology and Immunology, Medical Faculty of the University of Porto, Porto, Portugal.
  • Schmitt F; IPATIMUP - Institute of Molecular Pathology and Immunology, Medical Faculty of the University of Porto, Porto, Portugal.
  • Caldas C; Cancer Research UK Cambridge Research Institute Li Ka Shing Centre, Cambridge, UK.
  • Yarden Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel yosef.yarden@weizmann.ac.il.
EMBO Mol Med ; 7(3): 299-314, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25678558
ABSTRACT
Dissemination of primary tumor cells depends on migratory and invasive attributes. Here, we identify Navigator-3 (NAV3), a gene frequently mutated or deleted in human tumors, as a regulator of epithelial migration and invasion. Following induction by growth factors, NAV3 localizes to the plus ends of microtubules and enhances their polarized growth. Accordingly, NAV3 depletion trimmed microtubule growth, prolonged growth factor signaling, prevented apoptosis and enhanced random cell migration. Mathematical modeling suggested that NAV3-depleted cells acquire an advantage in terms of the way they explore their environment. In animal models, silencing NAV3 increased metastasis, whereas ectopic expression of the wild-type form, unlike expression of two, relatively unstable oncogenic mutants from human tumors, inhibited metastasis. Congruently, analyses of > 2,500 breast and lung cancer patients associated low NAV3 with shorter survival. We propose that NAV3 inhibits breast cancer progression by regulating microtubule dynamics, biasing directionally persistent rather than random migration, and inhibiting locomotion of initiated cells.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Movimento Celular / Proteínas de Membrana / Metástase Neoplásica / Proteínas do Tecido Nervoso Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: EMBO Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Movimento Celular / Proteínas de Membrana / Metástase Neoplásica / Proteínas do Tecido Nervoso Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: EMBO Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Israel